356 related articles for article (PubMed ID: 28378123)
1. Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.
Portillo MR; Rodríguez-Ortiz ME
Rev Endocr Metab Disord; 2017 Mar; 18(1):79-95. PubMed ID: 28378123
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
6. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
Brancaccio D; Cozzolino M; Galassi A; Bellasi A; Carpani P; Gallieni M
G Ital Nefrol; 2003; 20 Suppl 22():S12-6. PubMed ID: 12851915
[TBL] [Abstract][Full Text] [Related]
8. Advances in pharmacotherapy for secondary hyperparathyroidism.
Rodríguez M; Rodríguez-Ortiz ME
Expert Opin Pharmacother; 2015; 16(11):1703-16. PubMed ID: 26159447
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
11. Regulation of parathyroid function in chronic kidney disease (CKD).
Fukagawa M; Nakanishi S; Fujii H; Hamada Y; Abe T
Clin Exp Nephrol; 2006 Sep; 10(3):175-9. PubMed ID: 17009074
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid growth and suppression in renal failure.
Lewin E; Huan J; Olgaard K
Semin Dial; 2006; 19(3):238-45. PubMed ID: 16689976
[TBL] [Abstract][Full Text] [Related]
13. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
14. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
Drüeke TB
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
[TBL] [Abstract][Full Text] [Related]
16. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
[TBL] [Abstract][Full Text] [Related]
17. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
18. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
19. Renal secondary hyperparathyroidism in dogs.
Stillion JR; Ritt MG
Compend Contin Educ Vet; 2009 Jun; 31(6):E8. PubMed ID: 19746344
[TBL] [Abstract][Full Text] [Related]
20. Calcium and phosphorus in diet therapy of uremia.
Schoolwerth AC; Engle JE
J Am Diet Assoc; 1975 May; 66(5):460-4. PubMed ID: 1123506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]